{
  "study_metadata": {
    "study_id": "NCT01150955",
    "design": "RCT"
  },
  "exposure": {
    "label": "resveratrol",
    "comparator": "placebo"
  },
  "outcomes": [
    {
      "name": "FPG",
      "timepoint_weeks": 4,
      "arm_name": "intervention",
      "n": 12,
      "baseline_mean": 5.55,
      "baseline_sd": 0.485,
      "followup_mean": 5.55,
      "followup_sd": 0.346,
      "units": "mmol/L"
    },
    {
      "name": "FPG",
      "timepoint_weeks": 4,
      "arm_name": "control",
      "n": 12,
      "baseline_mean": 5.33,
      "baseline_sd": 0.277,
      "followup_mean": 5.33,
      "followup_sd": 0.45,
      "units": "mmol/L"
    },
    {
      "name": "HOMA_IR",
      "timepoint_weeks": 4,
      "arm_name": "intervention",
      "n": 12,
      "baseline_mean": 2.78,
      "baseline_sd": 0.138,
      "followup_mean": 2.94,
      "followup_sd": 0.173,
      "units": "unitless"
    },
    {
      "name": "HOMA_IR",
      "timepoint_weeks": 4,
      "arm_name": "control",
      "n": 12,
      "baseline_mean": 3.17,
      "baseline_sd": 0.138,
      "followup_mean": 3.19,
      "followup_sd": 0.138,
      "units": "unitless"
    },
    {
      "name": "HbA1c",
      "timepoint_weeks": 4,
      "arm_name": "intervention",
      "n": 12,
      "baseline_mean": 5.61,
      "baseline_sd": 0.173,
      "followup_mean": 5.52,
      "followup_sd": 0.173,
      "units": "%"
    },
    {
      "name": "HbA1c",
      "timepoint_weeks": 4,
      "arm_name": "control",
      "n": 12,
      "baseline_mean": 5.56,
      "baseline_sd": 0.173,
      "followup_mean": 5.42,
      "followup_sd": 0.173,
      "units": "%"
    }
  ],
  "comment_detailed": "The 4‑week high‑dose resveratrol trial in 24 obese men showed no significant changes in fasting glucose, HOMA‑IR, or HbA1c compared with placebo. Baseline and post‑treatment means and SEMs were extracted from Table 2; SDs were derived by multiplying SEM by √12. Both arms had 12 participants. No other glycaemic outcomes were reported. The study was a randomized, double‑blind, placebo‑controlled parallel‑group RCT (NCT01150955).",
  "missing_fields": [],
  "evidence": [
    "Table 2 shows baseline and after means for glucose, insulin, HOMA‑IR, HbA1c with SEMs.",
    "The study design is described as a randomized, double‑blind, placebo‑controlled, parallel‑group trial (NCT01150955)."
  ],
  "comment": "No effect of resveratrol on glycaemic control.",
  "confidence": 0.9
}